Interview with Murtaza Khorakiwala, Managing Director, Wockhardt
You joined Wockhardt in 2000; you became a member of the board in 2006, and were appointed managing director in 2009. The Indian industry has undergone many changes in the…
With a twenty year presence in a country that is projected to be amongst the top three pharmaceutical markets in 2021 by YOY growth, IQVIA India takes pride in its contribution to the growth of the Indian lifesciences industry. In parallel with the growth and development of the Indian healthcare industry, our clinical and commercial services have grown and expanded to encompass a wide portfolio today.
Contact:
Address: 902, 9th floor, B-Wing, Supreme Business Park, Hiranandani Gardens, Powai, Mumbai – 400076
Website: https://www.iqvia.com/locations/india
Email: amit.mookim@iqvia.com
You joined Wockhardt in 2000; you became a member of the board in 2006, and were appointed managing director in 2009. The Indian industry has undergone many changes in the…
Glenmark may be poised to release India’s first novel drug, from the in-licensed, anti-diarrheal molecule Crofelemer. Crofelemer has successfully complete Phase III trials, and you are readying to release it…
Since we last met in 2006, the Indian pharmaceutical industry has been doing very well indeed, as a very large number of drugs came off patent. This trend will continue…
Since we last met in 2006, the Indian pharmaceutical industry has been doing very well indeed, as a very large number of drugs came off patent. This trend will continue…
Our last report on India dates back to 2006, right after the Patent Law was passed. What developments have you seen happening in the industry since then? There has been…
“India, as a manufacturing hub, offers safe, effective, quality medicines, at the very best prices. Now, we are on our way to become a R&D hub.” For Dilip Shah, General…
See our Cookie Privacy Policy Here
